### **RESULT UPDATE**



#### **KEY DATA**

Rating	BUY
Sector relative	Outperformer
Price (INR)	2,021
12 month price target (INR)	2,331
Market cap (INR bn/USD bn)	147/2.0
Free float/Foreign ownership (%)	32.6/5.3
What's Changed	
Target Price	<b>1</b>
Rating/Risk Rating	_

#### **QUICK TAKE**

	Above	In line	Below
Profit	•		
Margins		•	
Revenue Growth	•		
Overall	•		

#### **FINANCIALS**

(INR mn)

			•	
Year to December	CY20A	CY21E	CY22E	CY23E
Revenue	19,818	21,405	23,043	24,692
EBITDA	4,993	6,036	6,590	7,087
Adjusted profit	3,547	4,362	4,786	5,223
Diluted EPS (INR)	48.9	60.1	65.9	71.9
EPS growth (%)	2.7	23.0	9.7	9.1
RoAE (%)	28.6	32.2	33.1	33.9
P/E (x)	41.4	33.6	30.7	28.1
EV/EBITDA (x)	27.7	22.7	20.5	18.8
Dividend yield (%)	1.6	1.7	2.0	2.2

#### PRICE PERFORMANCE



#### **Explore:**





Financial model





Corporate access

Video

# Improved traction across the board

Crisil's Q4CY20 revenue grew 28% YoY to INR5.9bn (18% above our estimate) driven by strong sales across segments: a 41% YoY spurt in research (-1% YoY adjusted for Greenwich acquisition) and a 7% YoY increase in ratings. EBITDA grew 27% YoY to INR1.5bn—22% above our estimate due to a much lower EBIT loss at Greenwich.

In the wake of fiscal expansionary policies, we expect ratings' sales to pick up in CY22 and research to scale up as Greenwich-related synergies are realised. Furthermore, new products and evolving regulations should lead to better traction in research. Factoring in a better business outlook, we are raising CY21/22E revenue by 2/5%. Retain 'BUY' with a revised TP of INR2,331 (37x Jun-22E EPS).

#### Ratings: Market share gains in a tepid environment

For Q4CY20, ratings revenue grew by 7% YoY (versus -6% YoY for CARE and -10% YoY for ICRA), and 4% YoY for CY20 led by high-quality ratings from large corporates, offsetting the dip in mid-corporate ratings. Bond issuances grew 8% YoY in value for CY20, but volumes fell 8% YoY as issuers dipped 18% YoY. Global Analytical Center (GAC) increased its coverage for S&P Global Ratings. Segmental EBIT margin declined 579bps YoY in Q4CY20. Ratings business is likely to see better traction in H2CY21, as credit growth picks up led by the government's expansionary policies.

#### Research: Greenwich and GR&A drive growth in sales and EBIT

Research sales grew 41% YoY in Q4CY20 led by the Global Research & Analytics business and contribution from Greenwich. The company saw strong demand for model and traded risk products, offset by a muted performance of Coalition. Ex-Greenwich, research dipped 1% YoY, while CY20 revenue grew 1%. Profit rose 15% YoY after eight quarters of decline driven by the Greenwich loss of merely INR7.7mn (INR200mn loss in previous two quarters). Management expects demand to pick up organically given new launches, evolving regulations (Dodd Frank stress test, etc) benefiting IREVNA, and delayed order book filling to benefit Coalition. Profitability should improve as synergies are realised from Greenwich (INR505mn loss in CY20).

### Outlook and valuation: Superior performance; maintain 'BUY'

Strong leadership position in the high-margin ratings segment and improving profitability in research continues to be encouraging. Maintain 'BUY/SO' with a revised TP of INR2,331 (earlier TP: INR2,230), valuing the stock at 37x Jun-22E EPS, average of past five years' band. The parent (S&P Global) is trading at 30x CY22E EPS.

#### **Financials**

Year to March	Q4CY20	Q4CY19	% Change	Q3CY20	% Change
Net Revenue	5,972	4,643	28.6	4,850	23.1
EBITDA	1,541	1,215	26.8	1,134	35.9
Adjusted Profit	1,100	953	15.4	902	22.0
Diluted EPS (INR)	15.3	13.2	15.4	12.5	22.0

Shradha Sheth

Meera Midha +91 (22) 4088 5804 Shradha.Sheth@edelweissfin.com Meera.Midha@edelweissfin.com

# **Financial Statements**

## Income Statement (INR mn)

Year to December	CY20A	CY21E	CY22E	CY23E
Total operating income	19,818	21,405	23,043	24,692
Gross profit	0	0	0	0
Employee costs	10,684	11,045	11,913	12,741
Other expenses	4,141	4,324	4,539	4,864
EBITDA	4,993	6,036	6,590	7,087
Depreciation	1,211	1,235	1,253	1,282
Less: Interest expense	144	129	120	120
Add: Other income	945	984	1,020	1,136
Profit before tax	4,583	5,656	6,237	6,821
Prov for tax	1,036	1,294	1,451	1,598
Less: Other adjustment	0	0	0	0
Reported profit	3,547	4,362	4,786	5,223
Less: Excp.item (net)	0	0	0	0
Adjusted profit	3,547	4,362	4,786	5,223
Diluted shares o/s	73	73	73	73
Adjusted diluted EPS	49	60	66	72
DPS (INR)	33.0	35.0	40.0	45.0
Tax rate (%)	22.6	22.9	23.3	23.4

# Balance Sheet (INR mn)

Data in the street (in the first)						
Year to December	CY20A	CY21E	CY22E	CY23E		
Share capital	73	73	73	73		
Reserves	13,046	13,940	14,877	15,830		
Shareholders funds	13,118	14,012	14,950	15,903		
Minority interest	0	0	0	0		
Borrowings	0	0	0	0		
Trade payables	1,054	726	783	838		
Other liabs & prov	4,397	4,397	4,397	4,397		
Total liabilities	20,629	21,196	22,191	23,198		
Net block	2,501	1,516	513	(519)		
Intangible assets	5,124	5,124	5,124	5,124		
Capital WIP	136	136	136	136		
Total fixed assets	7,761	6,776	5,772	4,741		
Non current inv	1,703	1,703	1,703	1,703		
Cash/cash equivalent	5,844	7,420	9,185	10,989		
Sundry debtors	3,074	3,049	3,283	3,518		
Loans & advances	458	458	458	458		
Other assets	1,790	1,790	1,790	1,790		
Total assets	20,629	21,196	22,191	23,198		

## **Important Ratios (%)**

Year to December	CY20A	CY21E	CY22E	CY23E
Rating (% of rev)	28.5	28.7	29.2	29.8
Research (% of rev)	64.7	64.5	63.8	63.0
Advisory (% of rev)	6.8	6.9	7.0	7.2
EBITDA margin (%)	25.2	28.2	28.6	28.7
Net profit margin (%)	17.9	20.4	20.8	21.2
Revenue growth (% YoY)	14.4	8.0	7.7	7.2
EBITDA growth (% YoY)	9.5	20.9	9.2	7.5
Adj. profit growth (%)	3.1	23.0	9.7	9.1

#### Free Cash Flow (INR mn)

(	,			
Year to December	CY20A	CY21E	CY22E	CY23E
Reported profit	3,547	4,362	4,786	5,223
Add: Depreciation	1,211	1,235	1,253	1,282
Interest (net of tax)	144	129	120	120
Others	1,199	669	617	763
Less: Changes in WC	153	(327)	57	54
Operating cash flow	5,005	4,774	5,383	5,844
Less: Capex	(2,861)	(250)	(250)	(250)
Free cash flow	2,144	4,524	5,133	5,594

#### Assumptions (%)

Year to December	CY20A	CY21E	CY22E	CY23E
GDP (YoY %)	(6.0)	7.0	6.0	6.0
Repo rate (%)	3.5	3.5	4.0	4.0
USD/INR (average)	75.0	73.0	72.0	72.0
Debt Issuances (% YoY)	14.0	15.0	15.0	15.0
Bank Credit (% YoY)	5.0	6.0	7.0	7.0
Debt Rated (INR bn)	10,700.4	12,305.5	14,257.7	16,396.4
BLR (New Assignments)	2,235.8	2,124.0	2,017.8	1,916.9
SME (Nos.)	10,799.2	12,311.1	14,034.6	15,999.5
Irevna (INR mn)	5,693.0	5,974.8	6,270.6	6,581.3

### **Key Ratios**

Year to December	CY20A	CY21E	CY22E	CY23E
RoE (%)	28.6	32.2	33.1	33.9
RoCE (%)	38.0	42.6	43.9	45.0
Inventory days	nm	nm	nm	nm
Receivable days	47	52	50	50
Payable days	nm	nm	nm	nm
Working cap (% sales)	(7.1)	(5.1)	(4.0)	(3.0)
Gross debt/equity (x)	0	0	0	0
Net debt/equity (x)	(44.5)	(53.0)	(61.4)	(69.1)
Interest coverage (x)	26.3	37.1	44.5	48.4

### **Valuation Metrics**

Year to December	CY20A	CY21E	CY22E	CY23E
Diluted P/E (x)	41.4	33.6	30.7	28.1
Price/BV (x)	11.2	10.5	9.8	9.2
EV/EBITDA (x)	27.7	22.7	20.5	18.8
Dividend yield (%)	1.6	1.7	2.0	2.2

#### Source: Company and Edelweiss estimates

#### **Valuation Drivers**

Year to December	CY20A	CY21E	CY22E	CY23E
EPS growth (%)	2.7	23.0	9.7	9.1
RoE (%)	28.6	32.2	33.1	33.9
EBITDA growth (%)	9.5	20.9	9.2	7.5
Payout ratio (%)	78.3	67.6	70.4	72.6

# Q3FY21 Conference all: Key takeaways

#### **Business environment**

- CY20 saw a severe economic slowdown across the globe with lockdowns, and normalcy only returning with lockdowns easing. Consequently, global GDP fell 4% YoY.
- India's GDP is expected to fall 7.7% in FY21, driven by a sharp reduction in revenue. Corporates (ex-BFSI and Oil) are expected to see 10-12% decline in revenues and 8-10% contraction in EBITDAs, cushioned by steel, telecom and cement.
- In 9mFY21 domestic credit growth slipped to 2.1%, with credit pick up across MSME and Retail sectors, owing to fiscal thrust on the same. Credit growth is likely to pick up in FY22.
- While bond issuances grew 8% in CY20, issuers were narrower as unique issuers fell 18% YoY, while no. of issuances reduced by 8% YoY. Majority of the successful fund raises were by AAA-rated companies and few AA-rated companies.
- CRISIL's credit ratio stood at 0.5, lowest in a decade. During CY20, downgrades
  were higher, however, various high frequency indicators witnessed trends
  reverse towards December. This is expected to move towards 1 with pick up in
  infrastructure and construction demand by H2FY22.
- Driven by volatility in capital markets, AUMs across domestic mutual funds and global CIB revenue pools are expected to do well in CY20, but should taper off in CY21.
- The infrastructure thrust in the budget should aid infrastructure advisory business.

#### **Ratings**

- As per SEBI mandate, the ratings business has been segregated to CRISIL Ratings Ltd. However, this should not have any business impact as the businesses were earlier separated by the Chinese Wall Policy.
- CY20 witnessed a continuation of flight to quality by investors. With this
  backdrop, the ratings segment registered healthy growth driven by performance
  of large corporate ratings. However, mid-corporate ratings remained impacted,
  offsetting the growth in the segment.
- GAC increased collaboration with SPGI on enhanced surveillance, data and transformation projects as well as partnered on ESG.
- Ratings business launched Ratings Analytica, a personalised portal and mobile application and hosted flagship events and webinars virtually to increase mind share.
- Debt markets are expected to improve in H2CY21 led by government infrastructure and spending, which is likely to improve lending. The government's efforts on creation of ARC and AMC should augur well for banks as they then focus on clean lending.
- Pricing for capital markets would be 2.5x the pricing for bank loan ratings.

#### Research

- CY20 was challenging ex of Greenwich, as lot of senior-level meets lead to business conversions, which got postponed.
- Management continues to see opportunities across regulatory tightening and maturing in Europe and US, while pockets of growth remain in Asia, which will benefit IREVNA.
- Research business saw strong performance driven by GR&A in traditional areas such as model and traded risk and acquisition of Greenwich. The business also saw traction in non-financial and credit risk. However, Coalition saw headwinds amidst cost tightening and delayed decision-making on mandates by clients.
   Order book are expected to pick up.
- CY20 includes one-time acquisition related costs and impact of covid as client decision-making slowed across markets.
- Despite challenges, Crisil launched India's first AIF benchmarks, and various new analytics and research including work on ESG.
- Greenwich accelerates Crisil's strategy to be the leading player in the global benchmarking analytics across financial services. It complements the existing Coalition CIB benchmarking products and expands offerings to commercial banking, asset and wealth managers. The acquisition was completed in Q1CY20. However, Greenwich was sharply impacted by the pandemic, especially the 'Voice of the Client' surveys as senior stakeholder data could not be taken. Clients were continuously engaged to and management focused on investing in the capability of Greenwich. The combination of the quantitative benchmarking of Coalition and qualitative benchmarking of Greenwich should be seen in CY21. During Q4CY20, performance of Greenwich improved, as part of migration and offshoring of the back-end processes were completed, which had taken a back seat in the covid period.
- While Irevna has witnessed pressures in the past, the business has been restructured to some of the emerging areas to support customers like ESG. The business faces a unique outlook with regulatory deadlines driving growth in Europe and US and economic challenges in Asia leading to growth in pockets.
- Management continues to witness traction for model and traded risks offerings with new risks emerging amidst covid and lockdowns.
- Crisil's investment in platforms and tools continued and aided in providing newer offerings to banks amidst covid.
- While margin has seen dips in the past few years owing to regulatory remediation, demand in model and traded risk has aided growth and the business witnessed margin expansion ex of Greenwich during CY20.
- Management sees opportunities across markets with evolving regulations. In US, maturing regulations like Comprehensive Capital Analysis and Review (CCAR), Dodd-Frank Act Stress Tests (DFAST), Current Expect Credit Loss (CECL), Fundamental Review of the Trade Book (FRTB), Interbank Lending Rate (IBOR) and Uncleared Margin Rules (UMR) Phase V and VI; in Europe tightening of regulations like European Banking Authority (EBA)/PRA stress testing, BASEL III, FRTB, Targeted Review of Internal Models (TRIM), IBOR and UMR Phase V and VI; and in Asia nascent regulations like IFRS 9, IBOR and Stress testing present opportunities.

### **Advisory**

- The infrastructure advisory business is likely to be aided by pro-growth budget.
   Management is increasing emphasis on end-to-end solutions and technology-enabled project monitoring dashboards.
- The risk solutions business has several proprietary models utilised by 90% of the banking industry. Management sees need for integrated credit and risk solutions, combining workflow and data analytics for clients, including digital enablement across financial services. This should see traction driven by move of financial firms from an on-premise model to cloud-enabled offerings.
- Management does not see the need to allocate much capex to the business, however, some capex will be incurred to push technology to the next level in risk solutions to enable readiness.
- The advisory business witnessed strong traction during Q4CY20 driven by new mandates, however, CY20 was impacted delayed decision making and implementation delays.
- Crisil launched portfolio impact assessment offering, to guide clients on addressing the impact of covid-19 and launched the new ICON platform with new-age risk assessment models.

**Exhibit 1: Performance by segment** 

	Q4CY20	Q4CY19	% YoY	Q3CY20	%QoQ
Segment revenue		<b>— — — — — — — — — —</b>		400120	7344
Rating Services	1,507	1,415	6.5	1,371	9.9
Advisory Services	398	340	16.9	321	23.9
Research Services	4,068	2,888	40.9	3,158	28.8
Total	5,972	4,643		4,850	
	-,-	,		,,,,,	
Segment EBIT					
Rating Services	580	626	(7.4)	519	11.7
Advisory Services	64	26	150.8	26	146.0
Research Services	711	619	14.8	355	100.3
Total	1,355	1,271		900	
Segment EBIT margin (%)					
Rating Services	38.5	44.3		37.9	
Advisory Services	16.1	7.5		8.1	
Research Services	17.5	21.4		11.2	

Source: Company, Edelweiss Research

**Exhibit 2: Quarterly financial snapshot** 

Year to December	Q4CY20	Q4CY19	YoY (%)	Q3CY20	QoQ (%)	CY20	CY21E	CY22E
Revenues	5,972	4,643	28.6	4,850	23.1	19,818	21,405	23,043
Employee cost	3,084	2,295	34.4	2,709	13.9	10,684	11,045	11,913
Other expenses	1,348	1,132	19.0	1,008	33.7	4,141	4,324	4,539
Total expenditure	4,432	3,428	29.3	3,716	19.3	14,826	15,369	16,453
EBITDA	1,541	1,215	26.8	1,134	35.9	4,993	6,036	6,590
Depreciation	313	93	235.2	327	(4.2)	1,211	1,235	1,253
EBIT	1,228	1,122	9.4	807	52.1	3,782	4,801	5,337
Less:-Interest Expense	37	1		36		144	129	120
Other income	150	200	-24.9	370	NM	945	984	1,020
Add: Exceptional items	0	0		0		0	0	0
PBT	1,341	1,321	1.5	1,141	17.5	4,727	5,785	6,357
Tax	240	368	-34.6	239	0.6	1,036	1,294	1,451
Reported Profit	1,100	953	15.4	902		3,547	4,362	4,786
Adjusted Profit	1,100	953	15.4	902	22.0	3,547	4,362	4,786
No. of Diluted shares outstanding (mn)	72	72		72		72	72	72
Adjusted Diluted EPS	15.3	13.2	15.4	12.5	22.0	48.9	60.1	65.9
as % of net revenues								
Staff expenses	51.6	49.4		55.8		53.9	51.6	51.7
Other expenses	22.6	24.4		20.8		20.9	20.2	19.7
EBITDA	25.8	26.2		23.4		25.2	28.2	28.6
Net profit	18.4	20.5		18.6		17.9	20.4	20.8

Source: Company, Edelweiss Research

Exhibit 3: Estimates increased by 2/5% for CY21/22 PAT

(INR mn) CY20			CY21			
(INK IIII)	Old	New	% Change	Old	New	% Change
Revenue	20907	21,405	2.4	22506	23,043	2.4
EBITDA	6042	6,036	(0.1)	6392	6,590	3.1
PAT	4276	4,362	2.0	4545	4,786	5.3

Source: Edelweiss Research

### **Company Description**

CRISIL is India's leading credit rating, research, risk & policy advisory company having pioneered the concept of credit rating in India in 1987. S&P, the world's leading credit rating agency by market share, is its major shareholder (67.7%) after the recent open offer.

CRISIL is a globally diversified analytical company having ratings, research and advisory services under its fold. With market leadership in corporate bonds, bank loan ratings and SME ratings, company is strongly poised to gain from cyclical and structural uptick in domestic ratings segment. With increased interest from parent, strong growth in off shoring services to S&P will continue which will drive its offshore ratings segment (Global Analytic Center). Being a global research analytics company providing off shoring services to several large global clients like 12 of top 15 global investment banks, two of the top 10 global consulting groups, three of the top 15 global insurance companies and 37 Fortune 500 companies, company is expected to continue its strong momentum in research revenues.

#### **Investment Theme**

CRISIL is India's leading credit rating company having an overall ~35% revenue market share, and a strong parentage—Standard & Poor (S&P), world's leading credit rating agency by market share. i) With consistent outperformance in high margin ratings, led by flight to safety post IL&FS crises by market participants; ii) improving bond market momentum; and iii) productivity gains in research we remain positive. Led by fiscal expansionary policies, we expect the ratings sales to pick up for the industry in 2H CY22. We are factoring in 8% CAGR in ratings sales over CY20-22E. We have assumed 7% CAGR in research revenue over the same time frame as demand picks up organically given new launches, evolving regulations presenting new opportunities and delayed order book filling up. With turnaround expected in CY21 in Greenwich, we expect 15% EBIDTA CAGR over CY20-22E.

#### **Key Risks**

#### Adverse macro economy

Ratings agencies are vulnerable to downturns in the economy when capital raising activities fall. Last year, fund raising activities dipped due to weakness in the economy and corporate level stress, which in turn led to reduced bond issuances and bonds rating businesses. Also with ~65% consolidated revenue from outside India, the company's overall revenue could face some pressure.

#### Pricing transience to fixed fee structure

Limited bond issuance and more so done by only the A category players pose a threat to rating agencies as issuances have transcended to a fixed fee cap structure. However, with CRISIL stronger among the A rated companies is gaining share post the IL&FS crises.

#### Risk of defaults

Any rating default by a client would hamper the credibility of the rating agency. However SEBI's mandatory disclosures of default rates and further improvement in disclosure norms would keep the rating agency under control of the watch guard.

# **Additional Data**

#### **Management**

Chairman	John Berisford
MD & CEO	Ashu Suyash
CFO	Sanjay Chakravarti
COO	Amish Mehta
Auditor	Walker Chandiok & Co

# Holdings – Top 10\*

	% Holding		% Holding
LIC of India	5.95	JP Morgan & Chase	0.52
General Insurance	3.31	ABSL AMC	0.51
Vanguard Group	0.83	BlackRock Inc	0.37
Brown Capital	0.81	Dimensional Fund	0.34
L&T MF	0.60	Invesco Ltd	0.32

<sup>\*</sup>Latest public data


### **Recent Company Research**

Date	Title	Price	Reco
24-Oct-20	Ratings decline, research strong; Result Update	1946.75	Buy
20-Oct-20	Ratings decline; research strong; Oven fresh	1870.8	Buy
25-Jul-20	CRISIL - Result Update Q1FY21 - Consiste; Result Update	1731	Buy

### **Recent Sector Research**


Date	Name of Co./Sector	Title
11-Feb-21	CARE Ratings	Transformation underway; Company Update
08-Feb-21	CARE Ratings	Growth on the anvil; Result Update
05-Nov-20	CARE Ratings	The tide turns; Result Update

## **Rating Interpretation**



Source: Bloomberg, Edelweiss research

## **Daily Volume**



Source: Bloomberg

#### **Rating Distribution: Edelweiss Research Coverage**

	Buy	Hold	Reduce	Total
Rating Distribution*	163	61	17	241
	>50bn	>10bn and <50bn	<10bn	Total
Market Cap (INR)	196	51	4	251

<sup>\*</sup> stocks under review

# **Rating Rationale**

Rating	Expected absolute returns over 12 months
Buy:	>15%
Hold:	>15% and <-5%
Reduce:	<-5%

#### **DISCLAIMER**

Edelweiss Securities Limited ("ESL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of ESL and its Associates (list available on www.edelweissfin.com) are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

This Report has been prepared by Edelweiss Securities Limited in the capacity of a Research Analyst having SEBI Registration No.INH200000121 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ESL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. ESL reserves the right to make modifications and alterations to this statement as may be required from time to time. ESL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. ESL is committed to providing independent and transparent recommendation to its clients. Neither ESL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The dis

ESL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the ESL to present the data. In no event shall ESL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the ESL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

ESL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. ESL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with ESL.

ESL or its associates may have received compensation from the subject company in the past 12 months. ESL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. ESL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. ESL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. ESL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or ESL's associates may have financial interest in the subject company. ESL and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. ESL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

ESL has financial interest in the subject companies: No

ESL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

ESL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by ESL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years except that ESL had submitted an offer of settlement with Securities and Exchange commission, USA (SEC) and the same has been accepted by SEC without admitting or denying the findings in relation to their charges of non registration as a broker dealer.

A graph of daily closing prices of the securities is also available at www.nseindia.com

#### Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

# **CRISIL**

#### Additional Disclaimers

#### Disclaimer for U.S. Persons

This research report is a product of Edelweiss Securities Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Edelweiss Securities Limited only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Edelweiss Securities Limited has entered into an agreement with a U.S. registered broker-dealer, Edelweiss Financial Services Inc. ("EFSI"). Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

#### Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

#### **Disclaimer for Canadian Persons**

This research report is a product of Edelweiss Securities Limited ("ESL"), which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst.

This report is intended for distribution by ESL only to "Permitted Clients" (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person.

ESL is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) ESL is not registered in the Province of Ontario to trade in securities nor is it registered in the Province of Ontario to provide advice with respect to securities; (ii) ESL's head office or principal place of business is located in India; (iii) all or substantially all of ESL's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against ESL because of the above; and (v) the name and address of the ESL's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario M5J 2T3 Canada

#### **Disclaimer for Singapore Persons**

In Singapore, this report is being distributed by Edelweiss Investment Advisors Private Limited ("EIAPL") (Co. Reg. No. 201016306H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to EIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact EIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors.

#### Disclaimer for Hong Kong persons

This report is distributed in Hong Kong by Edelweiss Securities (Hong Kong) Private Limited (ESHK), a licensed corporation (BOM -874) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to Section 116(1) of the Securities and Futures Ordinance "SFO". This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The report also does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of any individual recipients. The Indian Analyst(s) who compile this report is/are not located in Hong Kong and is/are not licensed to carry on regulated activities in Hong Kong and does not / do not hold themselves out as being able to do so.

Copyright 2009 Edelweiss Research (Edelweiss Securities Ltd). All rights reserved.

Aditya Narain Head of Research Aditya.Narain@edelweissfin.com